Skip to main content

Drug Interactions between Benylin Multi-Symptom and enflurane

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

pseudoephedrine enflurane

Applies to: Benylin Multi-Symptom (diphenhydramine / pseudoephedrine) and enflurane

GENERALLY AVOID: The administration of volatile general anesthetics during therapy with indirect-acting sympathomimetics (e.g. methylphenidate, ephedrine) or their derivatives may increase the risk of hypertension and/or cardiac arrhythmias. The proposed mechanism is anesthetic-induced myocardial sensitization to the stimulation caused by sympathomimetics.

MANAGEMENT: Until more information is available, caution is advisable if volatile general anesthetics are administered concomitantly with indirect-acting sympathomimetics or any of their derivatives. If the combination is required, dosage adjustments are recommended, and the patient's hemodynamic status should be closely monitored. When surgery is planned, it is recommended that indirect-acting sympathomimetics or their derivatives be discontinued prior to the day of surgery. Prescribing information for individual products should be consulted.

References (8)
  1. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
  2. (2022) "Product Information. Metadate CD (methylphenidate)." Celltech Pharmaceuticals Inc
  3. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  4. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  5. Cerner Multum, Inc. "Australian Product Information."
  6. (2013) "Product Information. Ritalin LA (methylphenidate)." Quality Care Products/Lake Erie Medical
  7. (2021) "Product Information. Azstarys (dexmethylphenidate-serdexmethylphenidate)." Corium, Inc.
  8. (2019) "Product Information. Isoflurane (isoflurane)." Piramal Critical Care Ltd

Drug and food interactions

Moderate

diphenhydrAMINE food

Applies to: Benylin Multi-Symptom (diphenhydramine / pseudoephedrine)

GENERALLY AVOID: Use of anticholinergic agents with alcohol may result in sufficient impairment of attention so as to render driving and operating machinery more hazardous. In addition, the potential for abuse may be increased with the combination. The mechanism of interaction is not established but may involve additive depressant effects on the central nervous system. No effect of oral propantheline or atropine on blood alcohol levels was observed in healthy volunteers when administered before ingestion of a standard ethanol load. However, one study found impairment of attention in subjects given atropine 0.5 mg or glycopyrrolate 1 mg in combination with alcohol.

MANAGEMENT: Alcohol should generally be avoided during therapy with anticholinergic agents. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.

References (1)
  1. Linnoila M (1973) "Drug effects on psychomotor skills related to driving: interaction of atropine, glycopyrrhonium and alcohol." Eur J Clin Pharmacol, 6, p. 107-12
Moderate

pseudoephedrine food

Applies to: Benylin Multi-Symptom (diphenhydramine / pseudoephedrine)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer